iShares Gold Trust vs Nuvation Bio Inc. Class A Common Stock — how do they compare? iShares Gold Trust trades at $78.67 (market cap $61.51B), while Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B). The key difference: iShares Gold Trust is far larger — about 35.4× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| IAU | NUVB | |
|---|---|---|
Market Cap | $61.51B | $1.74B |
Volume | 3,206,729 | 9,289,619 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $9.54 |
52-Week Low | $74.21 | $3.41 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $77.06, down 1.67% amid bearish technical signals with 13 of 13 moving averages indicating sell signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent soft inflation data has tempered rate-hike expectations. Support levels cluster around $76-77 while resistance sits at $78.
The outlook remains challenging with technical indicators overwhelmingly bearish and macroeconomic headwinds persisting. However, the RSI_12 reading of 25.07 suggests potential oversold conditions, creating possible tactical opportunities for contrarian investors despite the dominant downward trend.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →